Search company, investor...

AVAX Technologies

Founded Year



Unattributed VC - IV | Alive

Total Raised


Last Raised

$3.05M | 19 yrs ago

About AVAX Technologies

AVAX Technologies is a Healthcare/Biotechnology company based in Philadelphia, Pennsylvania. AVAX Technologies' investors include Precept Capital Management, Essex Woodland Health Ventures, PKB Privatbank AG, Soros Fund Management, Pequot Capital Mangement, Bank Julius Baer and Perot Investments.

Headquarters Location

2000 Hamilton Street Suite 204

Philadelphia, Pennsylvania, 19130,

United States


Missing: AVAX Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AVAX Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AVAX Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AVAX Technologies is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AVAX Technologies Patents

AVAX Technologies has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Vaccines, Clusters of differentiation, Immunology, Experimental cancer drugs, Oncology


Application Date


Grant Date


Related Topics

Vaccines, Clusters of differentiation, Immunology, Experimental cancer drugs, Oncology



Latest AVAX Technologies News

University of Tokyo to Evaluate AVAX's Breast Cancer Vaccine

Mar 20, 2017

AVAX Technologies Inc. (Kansas City, MO) and the University of Tokyo have entered into a collaborative research agreement to evaluate the application of the AVAX's patented AC Vaccine technology for the treatment of breast cancer. As part of the agreement, AVAX will provide the university with access to its technology in order to manufacture the vaccine for a clinical trial in Japan. The trial will be supported in part by a grant from the Noguchi Medical Foundation. AVAX's AC Vaccine technology is made from a patient's own cancer cells by modifying the tumor cells with a molecule called a hapten. This process, known as haptenization, alters the tumor cells and makes them appear foreign to the patient's immune system. When the hapten-modified cells are reinjected into patients, they stimulate the immune system to recognize the cancer cells and destroy them. AVAX is conducting a pivotal registration trial of the vaccine in malignant melanoma (M-Vax) and a Phase I/II trial in ovarian cancer (O-Vax) in the U.S. The collaborative research agreement with the University of Tokyo extends clinical development of the technology to a third indication. AVAX Technologies Inc. specializes in the development and commercialization of novel biotechnologies, immunotherapies, and pharmaceuticals for cancer and other life-threatening diseases. For more information: Jeffrey M. Jonas, President and CEO, AVAX Technologies Inc., 4520 Main St., Ste. 930, Kansas City, MO 64111. Tel: 816-960-1333. Fax: 816-960-1334. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .

AVAX Technologies Frequently Asked Questions (FAQ)

  • When was AVAX Technologies founded?

    AVAX Technologies was founded in 1990.

  • Where is AVAX Technologies's headquarters?

    AVAX Technologies's headquarters is located at 2000 Hamilton Street, Philadelphia.

  • What is AVAX Technologies's latest funding round?

    AVAX Technologies's latest funding round is Unattributed VC - IV.

  • How much did AVAX Technologies raise?

    AVAX Technologies raised a total of $39.27M.

  • Who are the investors of AVAX Technologies?

    Investors of AVAX Technologies include BNP Paribas, Matignon Technologies, Credit Suisse, FGS Advisors, SG Private Equity and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.